Motivators to participation in actual HIV vaccine trials

AIDS and Behavior

Volumn 18, Issue 2, 2014, Pages 263-277

  Dhalla, Shayesta ^a   Poole, Gary ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Actual; HIV; Motivators; Personal; Social; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ATTITUDE TO HEALTH; CLINICAL TRIAL (TOPIC); FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOTIVATION; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PSYCHOLOGICAL ASPECT; REVIEW;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; MOTIVATION; PATIENT COMPLIANCE; PATIENT PARTICIPATION;

EID: 84893832736     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-013-0519-8     Document Type: Review

References (26)

1. Dhalla S, Poole G. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care. 2011;23(11):1430-47.
2. Poole G. Using psychological principles to narrow the intention-behavior gap and increase participation in HIV vaccine trials. Curr HIV Res. 2012;10(6):552-6.
3. Becker MH. The health belief model and sick role behavior. Health Educ Monogr. 1974;2:409-19.
4. Luzi AM, Gallo P, Colucci A, Marcotullio S, Bellino S, Longo O, et al. Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein. AIDS Care. 2011;23(8):939-46.
5. Tarimo EA, Thorson A, Kohi TW, Bakari M, Sandstrom E, Mhalu F, et al. A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania. BMC Infect Dis. 2011;11:283.
6. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(4):266-71.
7. Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36(1):604-12. (Pubitemid 38544510)
8. OECD Members and Partners. Available at: http://www.oecd.org/about/ membersandpartners/. Accessed 28 Mar 2013.
9. Newman PA, Daley A, Halpenny R, Loutfy M. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine. 2008;26(8):1091-7.
10. Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown SJ, et al. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2004;37(3):1385-92. (Pubitemid 39435053)
11. Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39(3):359-64. (Pubitemid 40923219)
12. Vanichseni S, Tappero JW, Pitisuttithum P, Kitayaporn D, Mastro TD, Vimutisunthorn E, et al. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand. AIDS. 2004;18(2):311-6. (Pubitemid 38253455)
13. Pitisuttithum P, Choopanya K, Rerk-Ngnam S. HIV-vaccine research and development in Thailand: evolution and challenges. Vaccine. 2010;28(Suppl 2):B45-9.
14. Voytek CD, Jones KT, Metzger DS. Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection. Vaccine. 2011;29(36):6130-5.
15. Johnson MO. Belief of vaccine receipt in HIV vaccine trials: further cautions. J Acquir Immune Defic Syndr. 1999;21(5):413-6. (Pubitemid 29384004)
16. Thapinta D, Jenkins RA, Morgan PA, et al. Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2002;30(5):503-13.
17. Jenkins RA, Thapinta D, Morgan PA, et al. Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2005;40(5):592-9. (Pubitemid 41669165)
18. Lucero MC, Diaz-Brito V, Murillo BT, Carretero SC, Sala M, Casadesus C, et al. Reasons for not participating in a phase 1 preventive HIV vaccine study in a resource-rich country. AIDS Patient Care STDs. 2012;26(7):379-82.
19. Jenkins RA, Temoshok LR, Virochsiri K. Incentives and disincentives to participate in prophylactic HIV vaccine research. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9(1):36-42.
20. Crumbo CL, Rybczyk GK, Wagner LJ. Characteristics of volunteer participants in phase I HIV vaccine trials. J Assoc Nurses AIDS Care. 1997;8(5):59-65. (Pubitemid 127734436)
21. Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis. 2001;183(9):1343-52. (Pubitemid 32337116)
22. Gray K, Legg K, Sharp A, Mackie N, Olarinde F, De Souza C, et al. Participation in two phase II prophylactic HIV vaccine trials in the UK. Vaccine. 2008;26(23):2919-24.
23. Phanuphak P, Teeratakulpixarn S, Sarangbin S, et al. International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allergy Immunol. 1997;15(1):41-8. (Pubitemid 27356812)
24. Jenkins RA, Chinaworapong S, Morgan PA, Ruangyuttikarn C, Sontirat A, Chiu J, et al. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(2):171-7.
25. Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr. 2007;46(2):222-30. (Pubitemid 47482619)
26. Bakari M, Aboud S, Nilsson C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine. 2011;29(46):8417-28.